LifeMap Solutions Launches Full-Service Mobile Health App Design & Development to Meet the Needs of Medical, Research, & Comm...
April 25 2016 - 9:00AM
Business Wire
Digital health solutions provider makes its
ResearchKit and CareKit app expertise available to research
institutions and health companies worldwide to advance insights
into human health
LifeMap Solutions, the digital health subsidiary of BioTime,
Inc. (NYSE MKT: BTX) and co-developer of ResearchKit-enabled app
Asthma Health, today announced a new service to develop custom
smartphone apps and research studies for partners worldwide.
Through the new service, LifeMap offers clients its deep
expertise in medical science, consumer behavior, app analytics, and
design. LifeMap then adds the client’s own unique expertise to the
mix and guides the development, from concept to completion, of a
new research or care app and, optionally, a scientific study.
As the only commercial developer to participate in the launch of
Apple’s ResearchKit, LifeMap Solutions has garnered worldwide
attention for creating engaging, innovative, and data-driven mobile
health (mHealth) apps. LifeMap has worked closely with innovative
research institutions and commercial organizations such as the
Icahn School of Medicine at Mount Sinai, Stanford University School
of Medicine, the Mount Sinai – National Jewish Health Respiratory
Institute, and 23andMe.
“The ResearchKit revolution has struck a chord in the scientific
and medical industries,” said Corey Bridges, CEO of LifeMap
Solutions. “Research institutions, hospitals, and multinational
pharmaceutical companies have asked us to help them. They’ve
expressed a strong interest in breaking out of the ‘bricks and
mortar’ constraints of traditional research studies and care tools.
For research studies in particular, the benefits of using mHealth
best practices are extremely compelling: recruiting thousands of
study participants nationally or even internationally, obtaining
consent through the friendly interface of the iPhone, and passively
collecting participants’ health information. We’re entering a new
era of accelerated scientific discovery. And, with Apple’s new
CareKit platform, I expect we’ll see a similar revolution in
medical care. Thanks to our team’s unique skillset and experience,
I believe LifeMap Solutions will play a market-leading role as the
mHealth field evolves.”
In building research apps, LifeMap’s new app-design and creation
service follows a simple five-step process. The LifeMap Solutions
team works with partners to:
- Plan - integrate their design
into a secure mHealth platform and build a fully customized app
that satisfies study and consent requirements, delivered on time
and on budget.
- Review - work with a partner’s
Institutional Review Board (IRB) to facilitate approval of research
studies conducted through smartphones.
- Build - transform traditional
research elements into visually compelling and engaging apps.
- Launch - facilitate the app’s
launch by working with an institution’s own app-publishing team or
submitting the app directly into the App Store.
- Publish - help to best utilize
the data to further research and transform findings into scientific
articles and peer-reviewed publications with a team of highly
skilled data scientists.
Organizations interested in working with LifeMap Solutions can
learn more and contact the company here.
About LifeMap Solutions, Inc.
LifeMap Solutions develops innovative digital health solutions
by integrating health and wellness information with care team
guidance into a secure mHealth platform to deliver digital health
solutions that empower patients to make better choices to achieve
optimal health outcomes. LifeMap Solutions is a subsidiary of
BioTime, Inc., and is headquartered in San Jose, California. For
more information, please visit www.lifemap-solutions.com.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused
on developing and commercializing novel therapies developed from
what we believe to be the world’s premier collection of pluripotent
stem cell assets. The foundation of our core therapeutic technology
platform is pluripotent stem cells that are capable of becoming any
of the cell types in the human body. Pluripotent stem cells have
potential application in many areas of medicine with large unmet
patient needs, including various age-related degenerative diseases
and degenerative conditions for which there presently are no cures.
Unlike pharmaceuticals that require a molecular target, therapeutic
strategies based on the use of pluripotent stem cells are generally
aimed at regenerating or replacing affected cells and tissues, and
therefore may have broader applicability than pharmaceutical
products.
Forward-Looking Statements
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for BioTime and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the business of BioTime and
its subsidiaries, particularly those mentioned in the cautionary
statements found in BioTime's Securities and Exchange Commission
filings. BioTime disclaims any intent or obligation to update these
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160425005785/en/
Media Relations ContactsTriplePoint for LifeMap
Solutions415-955-8500lifemap@triplepointpr.comorGotham
Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.comorBioTime, Inc.Dan L. Lawrence,
510-775-0510dlawrence@biotimeinc.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024